JP2025509336A5 - - Google Patents

Info

Publication number
JP2025509336A5
JP2025509336A5 JP2024553553A JP2024553553A JP2025509336A5 JP 2025509336 A5 JP2025509336 A5 JP 2025509336A5 JP 2024553553 A JP2024553553 A JP 2024553553A JP 2024553553 A JP2024553553 A JP 2024553553A JP 2025509336 A5 JP2025509336 A5 JP 2025509336A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence described
hcdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509336A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/080090 external-priority patent/WO2023169419A1/en
Publication of JP2025509336A publication Critical patent/JP2025509336A/ja
Publication of JP2025509336A5 publication Critical patent/JP2025509336A5/ja
Pending legal-status Critical Current

Links

JP2024553553A 2022-03-09 2023-03-07 新規抗cd3抗体およびその使用 Pending JP2025509336A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2022079943 2022-03-09
CNPCT/CN2022/079943 2022-03-09
CN2022122679 2022-09-29
CNPCT/CN2022/122679 2022-09-29
CN2023077693 2023-02-22
CNPCT/CN2023/077693 2023-02-22
PCT/CN2023/080090 WO2023169419A1 (en) 2022-03-09 2023-03-07 Novel anti-cd3 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025509336A JP2025509336A (ja) 2025-04-11
JP2025509336A5 true JP2025509336A5 (cg-RX-API-DMAC7.html) 2026-03-16

Family

ID=87935966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553553A Pending JP2025509336A (ja) 2022-03-09 2023-03-07 新規抗cd3抗体およびその使用

Country Status (12)

Country Link
US (1) US20250223358A1 (cg-RX-API-DMAC7.html)
EP (1) EP4490194A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509336A (cg-RX-API-DMAC7.html)
KR (1) KR20240157737A (cg-RX-API-DMAC7.html)
CN (1) CN118974087A (cg-RX-API-DMAC7.html)
AU (1) AU2023232847A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245580A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013551A2 (cg-RX-API-DMAC7.html)
IL (1) IL315438A (cg-RX-API-DMAC7.html)
MX (1) MX2024010955A (cg-RX-API-DMAC7.html)
TW (1) TW202348630A (cg-RX-API-DMAC7.html)
WO (1) WO2023169419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2025014738A (es) * 2023-06-09 2026-02-03 Antengene Biologics Ltd Nuevos anticuerpos dirigidos a cd3 y otra diana y usos de los mismos
WO2025061993A1 (en) 2023-09-21 2025-03-27 Domain Therapeutics Anti-ccr8 monoclonal antibodies and their therapeutic use
CN122341642A (zh) 2023-09-21 2026-07-03 多曼治疗学公司 抗ccr8单克隆抗体及其治疗用途
WO2025119253A1 (en) * 2023-12-06 2025-06-12 Antengene (Hangzhou) Biologics Co., Ltd. Novel antibodies that bind to cd3 and lilrb4, and uses thereof
WO2025230233A1 (ko) * 2024-05-03 2025-11-06 국민대학교산학협력단 인간 cd3에 특이적인 항체 및 이의 용도
WO2026041038A1 (en) * 2024-08-20 2026-02-26 Antengene (Hangzhou) Biologics Co., Ltd. Novel anti-cdh6 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA94211C2 (ru) * 2004-06-03 2011-04-26 Новиммюн С.А. Выделенное полностью человеческое моноклональное cd3 антитело
HK1251480A1 (zh) * 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
CN118126180A (zh) * 2016-12-22 2024-06-04 第一三共株式会社 抗cd3抗体和包含所述抗体的分子
US11319371B2 (en) * 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
US11535667B2 (en) * 2017-08-28 2022-12-27 Systimmune, Inc. Anti-CD3 antibodies and methods of making and using thereof
CN111108119B (zh) * 2017-09-21 2022-11-15 上海药明生物技术有限公司 新型抗CD3ε抗体
TWI829667B (zh) * 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
BR112020023508A2 (pt) * 2018-05-24 2021-03-30 Janssen Biotech, Inc. Anticorpos anti-cd3 e usos dos mesmos

Similar Documents

Publication Publication Date Title
JP7438958B2 (ja) 新規な抗体分子、その調製方法及びその使用
TWI878355B (zh) 用於癌症治療之多重專一性結合蛋白
US20220411536A1 (en) Multispecific antibody
JP6708635B2 (ja) CD3εおよびROR1に対する二特異性抗体
US20200062858A1 (en) Trispecific antigen binding proteins
WO2023169419A1 (en) Novel anti-cd3 antibodies and uses thereof
WO2023236891A1 (en) Novel anti-lilrb4 antibodies and uses thereof
US20250368734A1 (en) Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
WO2024251242A1 (en) Novel antibodies targeting cd3 and another target and uses thereof
EP4413044A1 (en) Anti-cd3 monoclonal antibodies and therapeutic constructs
WO2024041315A1 (en) Novel anti-lilrb2 antibodies and uses thereof
JP2024514830A5 (cg-RX-API-DMAC7.html)
US20240156870A1 (en) Anti-egfr single domain antibodies and therapeutic constructs
TW202413417A (zh) 新穎抗cd3抗體及其用途